DO YOU HAVE LYNCH SYNDROME?

Dana-Farber Cancer Institute and Brigham & Women’s Hospital are enrolling patients with known or suspected Lynch Syndrome in a clinical trial looking at the safety and effects of Naproxen, a commonly used over-the-counter NSAID (non-steroidal anti-inflammatory drug), to prevent colon cancer.

MAJOR ELIGIBILITY CRITERIA INCLUDES:

- ≥18 years and older
- Positive genetic mutation for Lynch Syndrome
- Negative genetic testing for Lynch with Variant as result or Positive tumor testing (by IHC or MSI testing)
- No evidence of active / recurrent cancer for ≥6 months (including cancer treatment such as surgery, chemotherapy and radiation)

*other eligibility criteria may be determined by phone or in person

WHAT WILL HAPPEN IF YOU JOIN? These items are required for our study:

- A screening clinic visit for eligibility
- One (1) lower GI endoscopy with biopsies (coordinated with annual exam)
- One (1) flexible sigmoidoscopy with biopsies (covered by study)
- Donation of blood and urine samples
- Medications provided by the study**
- Diary to keep track of study drug use
- 5-6 Follow up phone calls

**Eligible participants will be randomized and given either Naproxen or placebo to take for 6 months. This study may or may not provide direct benefit but we hope it can benefit those in the future. Whether or not you decide to join the study, your current clinical care will not be affected.

Please call or email the research coordinator below for more information about the Naproxen Research Study:

Amanda Kirshkaln, Dr. Ramona Lim, MD
Research coordinator DFCI Principal Investigator
Office :( 617) 632-4788
Amanda_Kirshkaln@dfci.harvard.edu